Federal Register / Vol. 69, No. 243 / Monday, December 20, 2004 / Notices 75991

McKay (NINDS). U.S. Patent 

Application filed 14 Oct 2004 (DHHS 

Reference No. E–125–2004/0–US–01). 

Licensing Contact: Michael 

Shmilovich; 301/435–5019; 

shmilovm@mail.nih.gov.

Available for licensing and 

commercial development is a cell 

culture tool kit for etching confined 

growth areas on substrates coated with 

tissue culture growth matrix, such as 

fibronectin. The kit includes three 

components: an etching comb (etcher) 

with rectangular teats, a back plate, and 

an open chamber with guides to direct 

the etcher. 

Overview: Cells are plated over a glass 

cover slide previously coated with 

growth matrix. Perpendicular channels 

are etched into the culture, removing 

both growth matrix and plated cells, 

resulting in rectangular growth areas 

containing only the cells plated 

originally to each growth area. This 

protocol allows high-density cultures to 

grow freely within a confined growth 

area. Specifically, this procedure 

prevents emigration out of the growth 

area and also prevents immigration from 

individual cells or sphere clusters into 

the growth area, common if cells are 

plated on pre-defined surfaces. 

Method: A coated cover slide is plated 

with cells. The cover slide is then 

sandwiched between the back plate, and 

open chamber with etching guides, then 

secured in place. The chamber is filled 

with media and the etcher is drawn 

across the cover slip to generate a first 

set of channels. The etcher is then 

drawn across the cover slip in a 

perpendicular direction to generate a 

second set of channels, resulting in 

rectangular growth areas. The number of 

the teats on the etcher determines the 

number of squares in the grid, the width 

of each teat will determine the distance 

between the squares and the gap 

between the teats will determine the 

size of the squares. 

This tool kit enables the production of 

a slide for monitoring dynamic cell 

processes especially for the proliferation 

and migration of stem cells or other 

migratory cells. Beside complexity, a 

significant problem with existing 

containment systems is the inability to 

keep cells within the field of 

observation and to keep out cells not 

present in the field of view at the onset 

of the experiment. The present 

invention provides a simple and flexible 

solution that enables long-term cell 

culture in a defined growth area. 

Chlorine Dioxide Gas Decontamination 

Apparatus 

Deborah E. Wilson, D.Ph. (ORS). U.S. 

Provisional Application 60/620,095 

filed 18 Oct 2004 (DHHS Reference No. 

E–190–2004/0-US–01). 

Licensing Contact: Michael 

Shmilovich; 301/435–5019; 

shmilovm@mail.nih.gov.

Available for licensing and 

commercial development is an 

apparatus for decontaminating articles 

and areas contaminated with one or 

more biosafety level 2, 3, or 4 

pathogens. Particularly, the focus of 

decontamination is a piece of laboratory 

equipment, such as a biological safety 

cabinet. The apparatus is portable, and 

includes a moveable cart, a source of 

chlorine dioxide gas, a humidification 

means, an inlet conduit for introducing 

a flow of chlorine dioxide gas from the 

source of chlorine dioxide gas into the 

environment and for simultaneously 

humidifying the environment, and an 

outlet conduit for withdrawing gas from 

the environment. The apparatus further 

includes a blower for circulating gas 

between the environment to the 

humidifier and vice versa. Of particular 

advantage, the moveable cart weighs 

less than 200 pounds. The patent 

application covering this apparatus can 

be reviewed under a confidentiality 

nondisclosure agreement.

Dated: December 9, 2004. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health.

[FR Doc. 04–27723 Filed 12–17–04; 8:45 am] 

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing

AGENCY: National Institutes of Health, 

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing.

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Methods and Compositions for 

Protecting Cells From UltrasoundMediated Cytolysis 

Joe Z. Sostaric (NCI), Norio Miyoshi 

(EM), Peter Riesz (NCI). 

U.S. Provisional Application No. 60/

620,258 filed 19 Oct 2004 (DHHS 

Reference No. E–311–2004/0–US–01). 

Licensing Contact: Michael Shmilovich; 

301/435–5019; 

shmilovm@mail.nih.gov.

Available for licensing and 

commercial development are methods 

for protecting cells from ultrasoundmediated cytolysis. Therapeutic uses of 

ultrasound (e.g., sonoporation, 

thrombolysis, HIFU, sonophoresis, 

acoustic hemostasis) may induce 

changes in tissue state, including 

apoptosis and cytolysis, through 

thermal effects (e.g., hyperthermia), 

mechanical effects (e.g., acoustic 

cavitation or through radiation force, 

acoustic streaming and other ultrasound 

induced forces), and chemical effects 

(via sonochemistry or by the activation 

of solutes by sonoluminescence). 

Furthermore, ultrasound exposure 

conditions in biological processes, e.g.

ultrasound bioreactors, are limited by 

the need to decrease cytolysis of 

microbes or animal and plant cells. 

Accordingly, the protecting molecules 

used to carry out the methods of the 

invention possess the ability to protect 

cells against ultrasound mediated 

cytolysis, without hindering ultrasound 

induced physical effects that could be 

utilized to create beneficial effects. The 

protecting solutes are surface active and 

possess at least one ‘‘carbohydrate unit’’

as described. The solutes include, but 

are not limited to: alkyl-b-Dthioglucopyranoside, alkyl-b-Dthiomaltopyranoside, alkyl-b-Dgalactopyranoside, alkyl-b-Dthiogalactopyranoside, or alkyl-b-Dmaltrioside, hexyl-b-D-glucopyranoside, 

heptyl-b-D-glucopyranoside, octyl-b-Dglucopyranoside, nonyl-b-Dglucopyranoside, hexyl-b-Dmaltopyranoside, n-octyl-b-Dmaltopyranoside, n-octyl-b-Dthioglucopyranoside, 2-propyl-1-pentylb-D-maltopyranoside, methyl-6-O-(Nheptylcarbamoyl)-a-D-glucopyranoside, 

3-cyclohexyl-1-propyl-b-D-glucoside, 6-

O-methyl-n-heptylcarboxyl-a-Dglucopyranoside. 

In addition to licensing, the 

technology is available for further 

75992 Federal Register / Vol. 69, No. 243 / Monday, December 20, 2004 / Notices 

development through collaborative 

research with the inventors via a 

Cooperative Research and Development 

Agreement (CRADA). 

Treatment of Human Viral Infections 

(Imatinib) 

Drs. Steven Zeichner and Vyjayanthi 

Krishnan (NCI). 

U.S. Provisional Application No. 60/

588,015 filed 13 Jul 2004 (DHHS 

Reference No. E–281–2004/0–US–01). 

Licensing Contact: Sally Hu; 301/435–

5606; hus@mail.nih.gov.

This application describes the 

methods for treating or preventing a HIV 

infection by the administration of ablkinase inhibitor called imatinib and its 

derivatives. Several available agents can 

inhibit HIV replication by targeting one 

or another viral protein, such as the 

viral reverse transcriptase, protease, 

envelope fusion process, or integrase, or 

by targeting the interaction of a viral 

component with a host cell component, 

for example the host cell viral receptor 

or co-receptor. However, HIV can 

readily become resistant to these drugs, 

and new therapeutic approaches for HIV 

infection are needed. The studies 

described in the application show that 

the expression of many host cell genes 

changes in response to HIV replication, 

and show that targeting one of these 

changes with imatinib can inhibit viral 

replication. Thus targeting the host cell, 

and making the host cell less hospitable 

to the virus can inhibit viral replication. 

The application thus describes a new 

agent that inhibits viral replication by 

acting on the host cell, which may offer 

new approaches to therapy for HIV 

infection. These approaches may be less 

likely to engender rapid resistance in 

the virus to the therapy. 

This abstract replaces one published 

in the Federal Register on Friday, 

October 22, 2004 (69 FR 62060).

Dated: December 13, 2004. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health.

[FR Doc. 04–27780 Filed 12–17–04; 8:45 am] 

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing

AGENCY: National Institutes of Health, 

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing.

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: (301) 

496–7057; fax: (301) 402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

AAV4 Vector and Uses Thereof 

John A. Chiorini (NHLBI/NIDCR), 

Robert M. Kotin (NHLBI), Brian Safer 

(NHLBI). U.S. Patent 6,468,524 issued 

22 Oct 2002 (DHHS Reference No. E–

071–2000/0–US–01). 

Licensing Contact: Jesse Kindra; (301) 

435–5559; kindraj@mail.nih.gov. 

The invention described and claimed 

in this patent application relates to the 

delivery of heterologous nucleic acids or 

genes to particular target cells. In 

particular, the application relates to 

methods of delivering a heterologous 

nucleic acid or gene of interest to 

particular target cells using AdenoAssociated Virus of serotype 4 (AAV4). 

The particular target cells identified are 

the ependymal cells of the brain. The 

methods described herein may be useful 

in carrying out gene therapy for diseases 

of the brain or central nervous system. 

This work has been published in part 

at Davidson, BL, et al. ‘‘Recombinant 

adeno-associated virus type 2, 4, and 5 

vectors: transduction of variant cell 

types and regions in the mammalian 

central nervous system’’ PNAS USA 

97(7):3428–32 (March 28, 2000). 

In addition, PHS owns additional 

intellectual property related to this 

technology describing an AAV4-based 

vector system. The material contained 

in the patent application has been 

published as WO 98/11244 (March 19, 

1998) and the research corresponding 

thereto has been published in J. 

Virology 71(9): 6823–33 (Sept 1997). 

AAV5 Vector for Transducing Brain 

Cells and Lung Cells 

John A. Chiorini (NHLBI/NIDCR), 

Robert M. Kotin (NHLBI). 

U.S. Patent Application No. 09/

533,427 filed 22 Mar 2000 (DHHS 

Reference No. E–072–2000/0–US–01). 

Licensing Contact: Jesse Kindra; (301) 

435–5559; kindraj@mail.nih.gov. 

The invention described and claimed 

in this patent application is related to 

the delivery of heterologous nucleic 

acids or genes to particular target cells. 

In particular, the application relates to 

methods of delivering a heterologous 

nucleic acid or gene of interest to 

particular target cells using an AdenoAssociated Virus of serotype 5 (AAV5). 

The particular target cells identified 

include the alveolar cells of the lung 

and cerebellar and ependymal cells of 

the brain. The methods described herein 

may be useful in carrying out gene 

therapy related to diseases of the brain 

or central nervous system and the 

respiratory tract. 

This work has been published, in 

part, at Davidson BL, et al. PNAS, USA 

97(7):3428–32 (March 28, 2000) and 

Zabner J, et al. J Virol. 74(8):3852–8 

(April 2000). 

In addition to this patent application, 

PHS owns additional intellectual 

property related to this technology. The 

patent application has been published 

as WO 99/61601 on December 2, 1999 

and the research corresponding thereto 

has been published at Chiorini JA, et al.

J. Virol. 73(5): 4293–98 (May 1999) and 

Chiorini JA, et al. J. Virol. 73(2): 1309–

19 (Feb. 1999). 

TTP as a Regulator of GM-CSF mRNA 

Deadenylation and Stability

Ester Carballo-Jane, Wi S. Lai, Perry J. 

Blackshear (NIEHS). U.S. Provisional 

Application No. 60/148,810 filed 13 

Aug 1999 (DHHS Reference No. E–204–

1999/0–US–01); PCT Application No. 

PCT/US00/22199 filed 12 Aug 2000, 

which published as WO 01/12213 on 22 

Feb 2001 (DHHS Reference No. E–204–

1999/0–PCT–02); U.S. Patent 

Application No. 10/049,586 filed 12 Feb 

2002 (DHHS Reference No. E–204–1999/

0–US–03). 

Licensing Contact: Jesse Kindra; (301) 

435–5559; kindraj@mail.nih.gov. 

The disclosed invention provides 

materials and methods to treat 

granulocytopenia (low white cell count 

in the blood) which is characterized by 

a reduced number of granulocytes 

(relative) or an absence of granulocytes 

(absolute). This condition is commonly 

associated with cancer chemotherapy, 

but is seen less frequently in a number 

of conditions including the use of 

propylthiouracil, radiotherapy for 

marrow ablation for bone marrow 

transplantation, aplastic anemia, 

systemic lupus erythematosus, AIDS 

and a variety of other situations. The